154 related articles for article (PubMed ID: 10454987)
1. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers.
Zimmer A
Methods; 1999 Jul; 18(3):286-95, 322. PubMed ID: 10454987
[TBL] [Abstract][Full Text] [Related]
2. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides.
Zobel HP; Kreuter J; Werner D; Noe CR; Kümel G; Zimmer A
Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):483-93. PubMed ID: 9361907
[TBL] [Abstract][Full Text] [Related]
3. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.
Wartlick H; Spänkuch-Schmitt B; Strebhardt K; Kreuter J; Langer K
J Control Release; 2004 May; 96(3):483-95. PubMed ID: 15120904
[TBL] [Abstract][Full Text] [Related]
4. Comparison of antisense oligonucleotide drug delivery systems.
Weyermann J; Lochmann D; Zimmer A
J Control Release; 2004 Dec; 100(3):411-23. PubMed ID: 15567506
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
Aukunuru JV; Ayalasomayajula SP; Kompella UB
J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles in drug delivery.
Douglas SJ; Davis SS; Illum L
Crit Rev Ther Drug Carrier Syst; 1987; 3(3):233-61. PubMed ID: 3549008
[TBL] [Abstract][Full Text] [Related]
7. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ
Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463
[TBL] [Abstract][Full Text] [Related]
8. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
Weyermann J; Lochmann D; Georgens C; Zimmer A
Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
[TBL] [Abstract][Full Text] [Related]
9. Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation.
Dinauer N; Lochmann D; Demirhan I; Bouazzaoui A; Zimmer A; Chandra A; Kreuter J; von Briesen H
J Control Release; 2004 May; 96(3):497-507. PubMed ID: 15120905
[TBL] [Abstract][Full Text] [Related]
10. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles.
Liu Y; Franzen S
Bioconjug Chem; 2008 May; 19(5):1009-16. PubMed ID: 18393455
[TBL] [Abstract][Full Text] [Related]
11. Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis.
Qaddoumi MG; Gukasyan HJ; Davda J; Labhasetwar V; Kim KJ; Lee VH
Mol Vis; 2003 Oct; 9():559-68. PubMed ID: 14566223
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo transport and delivery of phosphorothioate oligonucleotides with cationic liposomes.
Miyano-Kurosaki N; Barnor JS; Takeuchi H; Owada T; Nakashima H; Yamamoto N; Matsuzaki T; Shimada F; Takaku H
Antivir Chem Chemother; 2004 Mar; 15(2):93-100. PubMed ID: 15185727
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Epstein Barr Virus LMP1 gene expression in B lymphocytes by antisense oligonucleotides: uptake and efficacy of lipid-based and receptor-mediated delivery systems.
Galletti R; Masciarelli S; Conti C; Matusali G; Di Renzo L; Meschini S; Arancia G; Mancini C; Mattia E
Antiviral Res; 2007 May; 74(2):102-10. PubMed ID: 17382835
[TBL] [Abstract][Full Text] [Related]
14. An antisense oligonucleotide carrier based on amino silica nanoparticles for antisense inhibition of cancer cells.
Peng J; He X; Wang K; Tan W; Li H; Xing X; Wang Y
Nanomedicine; 2006 Jun; 2(2):113-20. PubMed ID: 17292123
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes.
Hartmann G; Krug A; Bidlingmaier M; Hacker U; Eigler A; Albrecht R; Strasburger CJ; Endres S
J Pharmacol Exp Ther; 1998 May; 285(2):920-8. PubMed ID: 9580645
[TBL] [Abstract][Full Text] [Related]
16. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
Leamon CP; Cooper SR; Hardee GE
Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
[TBL] [Abstract][Full Text] [Related]
17. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
18. Requirements for delivery of active antisense oligonucleotides into cells with lipid carriers.
Jääskeläinen I; Lappalainen K; Honkakoski P; Urtti A
Methods Enzymol; 2004; 387():210-30. PubMed ID: 15172166
[No Abstract] [Full Text] [Related]
19. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides.
Chavany C; Le Doan T; Couvreur P; Puisieux F; Hélène C
Pharm Res; 1992 Apr; 9(4):441-9. PubMed ID: 1495887
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of aminoalkylmethacrylate nanoparticles as colloidal drug carrier systems. Part II: characterization of antisense oligonucleotides loaded copolymer nanoparticles.
Zobel HP; Stieneker F; Atmaca-Abdel Aziz S; Gilbert M; Werner D; Noe CR; Kreuter J; Zimmer A
Eur J Pharm Biopharm; 1999 Jul; 48(1):1-12. PubMed ID: 10477322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
